Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Ra Pharmaceuticals, Inc. (RARX)
|
Add to portfolio |
|
|
|
| Price: |
$45.95
| | Metrics |
| OS: |
47.3
|
M
| |
-39
|
% ROE
|
| Market cap: |
$2.17
|
B
| |
-779
|
% ROIC
|
|
Net cash:
|
$265
|
M
| |
$5.60
|
per share
|
|
EV:
|
$1.91
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($105)
|
M
| |
|
|
|
EBIT
|
($107)
|
M
| |
|
|
| EPS |
($2.34)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 3.0 | 2.5 | 0.0 | 4.9 | 4.1 | 4.8 |
| Revenue growth | 20.0% | | -100.0% | 20.4% | -15.2% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 3.0 | 2.5 | 0.0 | 4.9 | 4.1 | 4.8 |
| Gross margin | 100.0% | 100.0% | | 100.0% | 100.0% | 100.0% |
| Research and development | 82.6 | 54.4 | 45.3 | 27.9 | 15.2 | 10.0 |
| General and administrative | 27.3 | 14.4 | 9.8 | 5.0 | 2.2 | 1.9 |
| EBITA | -106.9 | -66.3 | -54.9 | -27.9 | -13.3 | -7.0 |
| EBITA margin | -3562.6% | -2651.5% | | -566.6% | -323.8% | -145.1% |
| Amortization of intangibles | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| EBIT | -107.0 | -66.4 | -55.0 | -28.0 | -13.4 | -7.1 |
| EBIT margin | -3566.0% | -2655.5% | | -568.7% | -326.2% | -147.2% |
| Pre-tax income | -102.7 | -65.0 | -54.5 | -28.9 | -14.0 | -5.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% | 0.5% |
| Net income | -102.7 | -64.9 | -54.4 | -28.9 | -12.3 | -5.5 |
| Net margin | -3422.9% | -2597.7% | | -585.7% | -299.7% | -113.4% |
| |
| Diluted EPS | ($2.31) | ($2.06) | ($2.41) | ($6.98) | ($24.69) | ($12.46) |
| Shares outstanding (diluted) | 44.4 | 31.5 | 22.6 | 4.1 | 0.5 | 0.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|